bjgabrielsen

FDA Approves a Highly Sensitive Prostate Cancer Imaging Agent

On May 26th, the FDA approved another highly sensitive imaging compound specifically for prostate cancer called 18F-DCFPyL. This is the second such approval in less than six months; in December 2020, the FDA approved 68Ga-PSMA-11 PET (gallium-68 PET scan). These pioneering new scanning tools will revolutionize prostate cancer detection. Both imaging agents are used to more »

Decipher Can Help Predict Metastasis and Whether Hormome Therapy is Needed in Recurrent Cancer.

Recurrent prostate cancer is usually treated with radiation alone or with the addition of hormone therapy. Doctors currently use certain criteria—like tumor grade and PSA level—to recommend whether patients with recurrent prostate cancer should get hormone therapy in addition to radiation. But studies have shown that these characteristics aren’t very good at identifying people who more »

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer

On Friday, December 18, 2020, the US FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix (Orgovyx), for adult patients with advanced prostate cancer. This is an important advance because it offers another option to patients who are taking hormone therapy. One of the mainstays of treatment for high-risk and metastatic prostate cancer more »

Long Term Hormone Therapy Raises Risk of Cardiovascular Death

If you have been on hormone therapy (androgen deprivation therapy, ADT) for significant periods of time, e.g. greater than six months, this blog has some valuable information and recommendation for you. A new study reports that long-term exposure to androgen deprivation therapy (ADT), a common treatment for prostate cancer, is associated with worse cardiorespiratory fitness more »

Finding Smallest Traces of Recurrent Cancer. FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as a positron emission tomography or PET imaging agent for men with prostate cancer. The molecule is the first approved PET imaging agent that detects prostate cancer lesions by targeting the prostate-specific membrane antigen (PSMA) — a protein produced at more »

FoundationOne Liquid CDx “Liquid Biopsy” Blood Test Gets Expanded FDA Approval

If you are considering genetic testing to identify whether a potential therapy might be useful against your prostate cancer, this article may be helpful to you. This test can help identify genetic changes such as BRCA1, BRCA2 and ATM mutations in which case a corresponding targeted drug, such as olaparib (Lynparza), may be useful. The more »

Study Finds That Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga.

Provenge (sipuleucel-T) by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration (hormone)-resistant prostate cancer (mCRPC) when added at any point in a treatment regimen, according to a real-life study in the U.S. The study, “A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T more »

Feeling Overwhelmed?

I hope today finds you all doing well and healthy. But, as cancer survivors, we all have had days wherein we were feeling overwhelmed either with the disease itself or our anxieties. So for those days, I pass along this message I recently received from YouVersion entitled “You Are Not Alone.” If you are unsure more »

PyL Prostate Cancer Imaging Agent Submitted to FDA for Approval

Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The new drug application (NDA) sent to the FDA includes a request for priority review, which if granted may shorten PyL’s regulatory review process from the usual more »

The Promise of Peace

Philippians 4:6-7 states as follows: “Be anxious for nothing, but in everything by prayer and supplication (asking humbly and earnestly), with thanksgiving, let your requests be made known to God; and the peace of God, which surpasses all understanding, will guard your hearts and minds through Christ Jesus.” Earlier this month, I needed to undergo more »

ExoDx Urine Prostate Test to Evaluate Risk of Aggressive Prostate Cancer Prior to First Biopsy.

The ExoDx Prostate Test is a non-invasive, non-digital rectal exam, urine test used as a risk assessment tool to provide risk probabilities for aggressive prostate cancer. The technology relies on cancer-specific genomic biomarkers found in the urine. The test analyzes three cancer-specific biomarkers found in the urine associated with aggressive prostate cancer: ERG, PCA and more »

New Guidelines for Care of Advanced Prostate Cancer

The American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have released new guidelines for the diagnosis and treatment of advanced prostate cancer, developed by a panel of experts. In addition to their own expertise and experience, panel members assessed data from 264 prostate cancer studies in developing more »